Clik here to view.
Endosense and Siemens ink cardiac ablation development deal
Endosense SA signed a deal with Siemens AG’s (NYSE:SI) healthcare unit to development cardiac ablation visualization software using its TactiCath "force-sensing" catheter for arrhythmia treatment. The...
View ArticleClik here to view.
Potential new risk factor for heart disease discovered | Research roundup
Here’s a roundup of recent clinical trial and scientific study news: Potential new risk factor for heart disease discovered Abnormal heart rate turbulence is associated with an increased risk of heart...
View ArticleClik here to view.
Sleep apnea: ImThera touts tongue stimulation treatment | Research roundup
ImThera Medical Inc. said its tongue stimulation device for sleep apnea can improve patients’ snooze time. The San Diego-based device maker concluded a European pilot study of its aura6000, an...
View ArticleClik here to view.
GE Healthcare and Endosense team up on all-in-one catheter ablation system
Endosense and GE Healthcare have inked a deal to jointly develop an all-in-one catheter ablation system for the treatment of cardiac arrhythmias. Endosense is merging tip-to-tissue data from its...
View ArticleEndosense names Keltjens President & CEO
GENEVA–(BUSINESS WIRE)–Endosense Names Jan Keltjens President and Chief Executive Officer The post Endosense names Keltjens President & CEO appeared first on MassDevice.
View ArticleClik here to view.
MIT’s Langer wins Alpert Prize | Personnel Moves
Bob Langer, MIT professor and bioengineering hot-shot, was chosen to recieve the 2011 Alpert Prize for his advancements in drug delivery and tissue engineering. Langer is the most-cited engineer in...
View ArticleClik here to view.
HRS 2012 Update: Ablation beats drugs in safety, efficacy in AF patients
Patients with a common heart rhythm disorder who received treatment with cardiac ablation were arrhythmia-free longer than patients taking drugs, suggesting that ablation should be a 1st-order...
View ArticleClik here to view.
Endosense CEO Keltjens goes to the races with TactiCath Quartz
Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson‘s (NYSE:JNJ) BioSense Webster division. Endosense,...
View ArticleClik here to view.
Catheter ablation tech maker Endosense closes $40M round
Cather ablation technology maker Endosense announced the close of a $40.3 million Series C funding round this week, supported by new and existing investors in the Geneva-based company. Funding was led...
View ArticleClik here to view.
EndoSense logs 1st U.S. use of new TactiCath Quartz ablation device
EndoSense said it’s logged the 1st use of its TactiCath Quartz contact-force sensing ablation catheter in a new arm of its Toccastar trial of the device. The TactiCath Quartz uses a force sensor to...
View ArticleClik here to view.
HRS13: Endosense’s force-sensing ablation catheter
Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week...
View ArticleClik here to view.
St. Jude Medical touches Endosense for $331M
St. Jude Medical (NYSE:STJ) said it agreed to pay up to $331 million, including $170 million in up-front cash, for Swiss force-sensing catheter maker Endosense. St. Paul, Minn.-based St. Jude said the...
View ArticleClik here to view.
Report: Smith & Nephew chairman Buchanan to step down | Personnel Moves
Sir John Buchanan, the chairman of Smith & Nephew (FTSE:SN, NYSE:SNN), is reportedly getting ready to step down from the medical device giant’s board of the directors at the end of the month. The...
View ArticleClik here to view.
J&J’s Biosense Webster wins PMA nod from FDA for force-sensing catheter
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster subsidiary said it won pre-market approval from the FDA for its ThermoCool SmartTouch force-sensing ablation catheter, making it the 1st such device...
View Article
